Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program

• Published in: Fertility and sterility Vol. 93; no. 2; pp. 374 - 378
• Main Authors: Erb, Teresa M., M.D, Vitek, Wendy, M.D, Wakim, Anthony N.G., M.D
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 2010; Elsevier
• Subjects: Adult; Biological and medical sciences; Chorionic Gonadotropin - therapeutic use; Estradiol - blood; Female; Follicle Stimulating Hormone - blood; GnRH agonist; Gonadotropin-Releasing Hormone - agonists; Gonadotropin-Releasing Hormone - analogs & derivatives; Gonadotropin-Releasing Hormone - therapeutic use; Gynecology. Andrology. Obstetrics; hCG; Hormone Antagonists - therapeutic use; Humans; Intercellular Signaling Peptides and Proteins - pharmacology; Internal Medicine; Leuprolide - therapeutic use; Medical sciences; Obstetrics and Gynecology; Oocyte Donation; Oocyte donor; oocyte maturation; Oocytes - drug effects; Oocytes - physiology; Ovarian Follicle - cytology; Ovarian Follicle - drug effects; Ovulation Induction; Pregnancy; Retrospective Studies; Young Adult; oocyte maturation; Oocyte donor; hCG; GnRH agonist; pregnancy; Human; Agonist; Gynecology; Gonadotropin RH; Obstetrics; Pregnancy; Protein hormone; Human chorionic gonadotrophin; Donor; Chorionic gonadotrophin; Oocyte; Oocyte maturation
• ISSN: 0015-0282; 1556-5653
• DOI: 10.1016/j.fertnstert.2008.12.015

Objective To compare leuprolide acetate to hCG as the trigger for final oocyte maturation in oocyte donor cycles. Design Retrospective review. Setting Academic IVF donor program. Patient(s) Thirty-two healthy oocyte donors aged 21–33 years with adequate ovarian reserve. Intervention(s) Donors were down-regulated with cetrorelix and received either leuprolide acetate (n = 12) or hCG (n = 20) for final oocyte maturation. Main Outcome Measure(s) Embryo number, embryo quality, fertilization, implantation, clinical pregnancy, and ovarian hyperstimulation syndrome rates. Result(s) The numbers of total oocytes (23 vs. 15), mature (metaphase II) oocytes (22 vs. 13), embryos (15 vs. 10), and cryopreserved embryos (12 vs. 6) per treatment cycle were significantly greater in the leuprolide arm than in the hCG arm. Fertilization rates (73% vs. 78%), implantation rates (30% vs. 29%), and clinical pregnancy rates (40% vs. 50%) were not statistically different between the arms. There were no cases of ovarian hyperstimulation syndrome. Conclusion(s) Leuprolide acetate–triggered oocyte donor cycles yielded similar fertilization, implantation, and clinical pregnancy rates to hCG-triggered cycles.